HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $622K invested in HTG Molecular Diagnostics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
81% less capital invested
Capital invested by funds: $3.19M → $622K (-$2.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$77.4K |
| 2 |
Renaissance Technologies
New York
|
+$77K |
| 3 |
BlackRock
New York
|
+$47K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$44.9K |
| 5 |
Citigroup
New York
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.16M |
| 2 |
SC
Samjo Capital
New York
|
-$563K |
| 3 |
CPA
Cowen Prime Advisors
New York
|
-$462K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$397K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$133K |
HTGM Hedge Fund Activity: Q2 2022 in Review
21 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2022, worth a combined $622K — down 81% from $3.19M a quarter earlier.
Fund positioning in HTGM was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $77.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.16M sold.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $622K of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2022, down 81% quarter-over-quarter.
- 4 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2022 was Susquehanna International Group, an estimated $77.4K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2022 was Armistice Capital, an estimated $1.16M sold.
Based on aggregated 13F filings for Q2 2022.